Auna (AUNA) Q3 2026 Earnings Call Transcript

Auna (AUNA) reported Q3 2026 earnings, highlighting 10% top-line growth on an FX-neutral basis. Mexico saw accelerated growth and profitability, while Colombia faced medical cost pressures. Peru's revenue grew, but profitability declined due to penalties. The company maintained strong cash generation, reducing leverage to 3.5x. Auna remains confident in its long-term growth potential.

Original reporting
Published Nov 18, 2026, 9:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Auna (AUNA) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$AUNABearishMed
01

Why it matters

The transcript discloses segment-level profitability pressures (Colombia oncology contract adverse costs and regulatory price caps) alongside improving cash conversion and leverage progress, which can drive near-term valuation debate around margin durability versus growth.

02

Market read

Traders can reassess near-term margin risk in Colombia versus strength in Mexico and Peru, using the call’s explicit drivers (contract termination, price caps, penalties, and volume/utilization metrics).

03

What to watch

Mexico’s VAT deductibility headwinds are described as offset by network volume growth, so the consolidated story may be more resilient than segment EBITDA implies if utilization trends persist.

Relevance 7/10Novelty 6/10Timing: during/after the Q3 2026 earnings call, with segment-specific margin headwinds highlighted

Background

The article is a transcript of Auna’s Q3 2026 earnings call, covering regional performance (Mexico, Peru, Colombia), cash generation, leverage, and specific contract and regulatory drivers.

Company-level read

Ticker impact

$AUNABearishMedium confidence
Context

Auna reports Q3 growth and cash generation, but flags Colombia oncology contract losses and regulatory price caps pressuring segment EBITDA.

Expected impact

Likely downside bias as investors focus on Colombia margin pressure and the terminated risk-sharing contract, despite solid consolidated revenue and free cash flow.

Evidence & confidence

The call provides specific drivers for segment EBITDA declines (about 4% of Colombia revenue adverse costs, contract termination, and ongoing price-cap impact) alongside stronger Mexico and Peru metrics, implying mixed but net risk to margins.

Market effects

Highlights how oncology risk-sharing contract economics and regulatory price caps can quickly swing profitability for integrated healthcare providers.

Colombia is the key swing factor due to contract-driven adverse medical costs and mid-August price caps.

Limited direct global read-through, but reinforces investor sensitivity to healthcare reimbursement regulation and contract risk management.

Counterpoint

Termination of the problematic Colombia oncology risk-sharing contract and active legal recovery efforts could reduce future downside more than the current quarter suggests.

Key entities

  • Auna

    Integrated healthcare provider reporting Q3 2026 results and discussing segment profitability drivers in Mexico, Peru, and Colombia.

  • IMAT Oncomédica

    Colombia facility where Auna expanded ICU and hospitalization capacity to support high-complexity demand.

  • Oncosalud

    Peru oncology platform referenced for oncology MLR and plan membership growth.

Related articles

$AUNAMed

Auna S.A. (AUNA) Stock Falls on Q3 2026 Earnings

Auna S.A. (AUNA) reported Q3 2026 revenue of $384.7M, up 19.4% YoY, with net income falling 57.4% to $5.9M. Operating cash flow rose 38.9% to $77.6M. Insiders made 6 purchases and 1 sale in the past 6 months. Hedge funds showed mixed activity, with some increasing and others decreasing positions.

$AUNAMed

AUNA S.A. (AUNA): Financial results for Q3 2026

AUNA S.A. (AUNA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Auna Announces 3Q26 Financial Results Auna reports 10% FX-Neutral Revenue Growth and Continued Strong Cash Generation in 3Q2026; Mexico Returns to Year-over-Year Adjusted EBITDA Growth; Profitability Pressured by Specific Headwinds in Colombia and Peru Leverage Impro

$AUNAHigh

Why is Auna stock dropping today?

Auna SAA ADR stock fell 9.2% to $4.91 after revising its 2026 profitability outlook, citing higher cancer diagnosis costs in Colombia. The company maintained its revenue growth target but saw a sell-off amid broader market declines. The stock dropped to a session low of $4.55, nearing its 52-week low of $4.09.

$AUNAMed

Auna (AUNA) Q2 2026 Earnings Call Transcript

Auna (AUNA) reported Q2 2026 results with 9% revenue growth driven by volume and higher complexity services. Adjusted EBITDA declined 9% due to margin pressures in Mexico and Colombia, and billing penalties in Peru. Mexico saw 7% surgery and 20% oncology volume growth, while Peru achieved 8% revenue growth. Colombia's adjusted EBITDA increased 18% sequentially. Leverage decreased to 3.6x, and cash increased 43% year-over-year.